Premium
Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer
Author(s) -
Pelster Meredith S.,
Mott Frank,
Lewin Jan
Publication year - 2020
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28038
Subject(s) - medicine , pembrolizumab , mucositis , head and neck cancer , oncology , squamous cell cancer , regimen , head and neck , cancer , chemotherapy , immunotherapy , surgery , dermatology
Pembrolizumab, an anti‐PD‐1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum‐based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune‐mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope , 130:E140–E143, 2020